Headache and Migraine

Patients with a previous history of cardiovascular risks experienced similarly low number of cardiovascular events with treatment of fremanezumab compared with placebo.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.

Here's what is coming soon to NeurologyLive.

Serious adverse events occurred in 3.7% and 2.4% of subjects in the subgroups of patients with 1 and 2 or more triptan failures, respectively.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

Jill Dehlin, RN, a patient with migraine, talks about her experience receiving a subcutaneous injectable CGRP inhibitor, and neurologist Jessica Ailani, MD, explains what she counsels her patients on when prescribing a newer injectable treatment. 

Jessica Ailani, MD, a neurologist from MedStar Health, shares insight on best practices for dosing therapies used to treat migraine and implications for combining drugs together.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending April 10, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 9, 2021.

Variables that neurologists and other healthcare professionals need to consider when selecting an appropriate prescription therapy for migraine, and recommendations by a patient advocate on staying adherent to therapy and predicting attacks.

Limitations, in terms of safety and efficacy, of older conventional therapies used to treat migraine.

Patients with a history of abuse reported a higher average or median questionnaire scores that focused on anxiety, depression, photophobia, hyperacusis, ictal allodynia, and interictal allodynia.

The chief medical officer of Biohaven Pharmaceuticals discussed the recently initiated phase 2/3 clinical trial of zavegepant for the prevention of migraine.

Here's what is coming soon to NeurologyLive.

The randomized, double-blind, placebo-controlled trial will enroll approximately 2900 people with migraine and will evaluate the efficacy and safety of 100- and 200-mg zavegepant.

Neurology News Network for the week ending April 3, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 2, 2021.

Neurologist Jessica Ailani, MD, explains when she feels it is most appropriate to treat migraine more aggressively with prescription drugs versus with lifestyle intervention.

Jessica Ailani, MD, describes her approach to evaluating new patients for migraine and explains how her diagnostic work-up can impact her recommendations for treatment.

In the phase 3 ADVANCE trial, all active treatment arms of atogepant met their primary end point, and the 30-mg and 60-mg doses met all 6 secondary end points with statistical significance.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.